Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

19.810
-0.530-2.61%
Volume:2.06M
Turnover:41.20M
Market Cap:22.54B
PE:-15.77
High:20.600
Open:20.300
Low:19.750
Close:20.340
52wk High:27.360
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:0.38
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.256
ROE:-26.91%
ROA:-14.75%
PB:4.74
PE(LYR):-15.77
PS:6.40

Loading ...

BRIEF-Zai Lab Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy

Reuters
·
Apr 01

Zai Lab, Amgen partner on global trial of DLL3 ADC with Imdelltra in SCLC

Reuters
·
Apr 01

Zai Lab Ltd - Announces Global Clinical Trial Collaboration With Amgen for Es-Sclc

THOMSON REUTERS
·
Apr 01

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Dll3 ADC, Zocilurtatug Pelitecan, in Combination With a Bispecific T-Cell Engager Therapy

THOMSON REUTERS
·
Apr 01

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

Reuters
·
Mar 27

Zai Lab files next day disclosure return with Hong Kong Stock Exchange; share capital rises by 6,000,000 shares at HKD 0

Reuters
·
Mar 27

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

Zai Lab's 2025 Loss Narrows by 32% as Revenue Jumps 15%

MT Newswires Live
·
Mar 27

Zai Lab Reports Fiscal Year Results with 15% Revenue Growth to $460 Million and Positive Pipeline Updates

Stock News
·
Mar 27

Zai Lab 2025 Results: Revenue Rises 15%, Net Loss Contracts 32%

Bulletin Express
·
Mar 27

Zai Lab - FY Net Loss $175.5 Mln

THOMSON REUTERS
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

arGEN-X FY 2025 profit rose 55% to USD 1.29 billion as product net sales climbed 90% to USD 4.15 billion

Reuters
·
Mar 19

Zai Lab to present Phase 1 trial data on DLL3-targeting ADC ZL-1310 at AACR 2026

Reuters
·
Mar 18

HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Tiger Newspress
·
Mar 17

Zai Lab (09688) Schedules 26–27 Mar Board Meeting to Approve 2025 Annual Results; HK Release to Align with U.S. GAAP Filing

Bulletin Express
·
Mar 16

Zai Lab grants CEO Samantha Du 3.53 million share options under 2024 equity incentive plan

Reuters
·
Mar 13

Zai Lab Issues Equity Incentives Including Stock Options and Restricted Units

Stock News
·
Mar 13

Zai Lab Issues Stock Options, Restricted Share Units, and Performance Share Units

Stock News
·
Mar 09